首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1461331

脊髓性肌肉萎縮症市場，按類型、治療、年齡層、給藥途徑、配銷通路和地區 - 規模、佔有率、前景和機會分析，2024 年至 2031 年

Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

出版日期: 2024年03月11日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2024 年，全球脊髓性肌肉萎縮症市場價值將達到 20.135 億美元，預計在預測期內（2024-2031 年）複合年成長率為 13.3%。

報告範圍		報告詳情
基準年：	2023年	2023/2024 年市場規模：	20.135 億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測期間 2023/2024 至 2030/2031 年複合成長率：	13.30%	2030/2031 價值預測：	48.239 億美元

2024 年全球脊髓性肌肉萎縮症市場價值（百萬美元），依地區分類

脊髓性肌肉萎縮症 (SMA) 是一種影響週邊神經系統、中樞神經系統和隨意肌肉運動（骨骼肌）的遺傳性疾病。 SMA 是肌肉性的，因為它主要影響肌肉，而肌肉不會接收來自神經細胞的脈衝。萎縮是收縮的醫學術語，這是肌肉在不受神經細胞刺激時所做的事情。 SMA 是一種運動神經元疾病，包括脊髓中稱為運動神經元的神經細胞的損失。它主要影響嬰兒和兒童，但也可能發生在成人中。患有 SMA 的個體繼承了兩個有缺陷（突變）或缺失的運動神經元存活基因 1 (SMN1) 基因。

市場動態

市場主要參與者不斷推出的產品預計將在預測期內推動市場成長。例如，2021年8月，日本藥品製造商中外製藥株式會社宣布推出Evrysdi乾糖漿60毫克（通用名：risdiplam），用於治療脊髓性肌肉萎縮症（SMA）。

此外，主要參與者擴大採用無機策略，例如夥伴關係和協作，預計將在預測期內推動市場成長。例如，2021 年 3 月，全球 SMA 研究的主要資助者脊髓性肌肉萎縮症基金會與美國製藥公司 PTC Therapeutics, Inc. 達成新的合作，專注於開發新療法和再生醫學，以進一步推進SMA 和其他神經肌肉疾病的科學研究。

研究的主要特點：

該報告對全球脊髓性肌肉萎縮症市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數介紹了全球脊髓性肌肉萎縮症市場的主要參與者 - 公司亮點、產品組合、主要亮點、財務表現和策略。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球脊髓性肌肉萎縮症市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師1。
利害關係人可以透過用於分析全球脊髓性肌肉萎縮症市場的各種策略矩陣輕鬆做出決策。

介紹
北美洲
美國
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地區
歐洲
英國
德國
義大利
法國
西班牙
俄羅斯
歐洲其他地區
亞太地區
中國
印度
日本
東協
澳洲
韓國
亞太地區其他地區
中東
海灣合作理事會
以色列
中東其他地區
非洲
北非
中非
南非

第 11 章：競爭格局

Biogen
CYTOKINETICS
F. Hoffmann-La Roche Ltd
Genentech, Inc.
PTC Therapeutics, Inc.
Novartis AG
Ionis Pharmaceuticals
Chugai Pharmaceutical Co., Ltd.
NMD PHARMA A/S
Astellas Pharma Inc.

第 12 章：分析師建議

命運之輪
分析師觀點
連貫的機會圖

第 13 章：部分

參考
研究方法論

簡介目錄

Product Code: CMI1920

Global spinal muscular atrophy market is estimated to be valued at USD 2,013.5 Mn in 2024 and is expected to exhibit a CAGR of 13.3% during the forecast period (2024-2031).

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 2,013.5 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	13.30%	2030/2031 Value Projection:	US$ 4,823.9 Mn

Global Spinal Muscular Atrophy Market Value (US$ Mn), by Region, 2024

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study:

This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Detailed Segmentation:

Global Spinal Muscular Atrophy Market, By Type:
- Type I
- Type II
- Type III
- Type IV
Global Spinal Muscular Atrophy Market, By Treatment:
- Gene Therapy
- Disease-modifying drugs
Global Spinal Muscular Atrophy Market, By Age Group:
- Infant
- Adult
Global Spinal Muscular Atrophy Market, By Route of Administration:
- Oral
- Injectables
Global Spinal Muscular Atrophy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Spinal Muscular Atrophy Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Company Profiles
- Biogen
- CYTOKINETICS
- Hoffmann-La Roche Ltd
- Genentech, Inc.
- PTC Therapeutics, Inc.
- Novartis AG
- Ionis Pharmaceuticals
- Chugai Pharmaceutical Co., Ltd.
- NMD PHARMA A/S
- Astellas Pharma Inc

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment
- Market Snapshot, By Age
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Acquisitions and Partnerships Scenario
Technological Advancements
Regulatory Scenario
PEST Analysis
Product Launches

4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Spinal Muscular Atrophy Market, By Type, 2019 - 2031, (US$ Million)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Type I
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Type II
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Type III
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Type IV
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

6. Global Spinal Muscular Atrophy Market, By Treatment, 2019 - 2031, (US$ Million)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Gene Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Disease-modifying drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

7. Global Spinal Muscular Atrophy Market, By Age, 2019 - 2031, (US$ Million)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Infant
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Adult
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2019 - 2031, (US$ Million)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Injectables
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2019 - 2031, (US$ Million)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Million)

10. Global Spinal Muscular Atrophy Market, By Region, 2019 - 2031, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
UK
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Age, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (US$ Million)
North Africa
Central Africa
South Africa

11. Competitive Landscape

Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CYTOKINETICS
F. Hoffmann-La Roche Ltd
Genentech, Inc.
PTC Therapeutics, Inc.
Novartis AG
Ionis Pharmaceuticals
Chugai Pharmaceutical Co., Ltd.
NMD PHARMA A/S
Astellas Pharma Inc.